During neutrophil recovery following hematopoietic stem cell transplantation, a constellation of symptoms and signs including fever, erythrodermatous skin rash, and noncardiogenic pulmonary edema often occur. These clinical findings have usually been referred to as engraftment syndrome, or, reflecting the manifestations of increased capillary permeability, capillary leak syndrome. While described most often following autologous stem cell transplantation, a similar clinical syndrome has been observed followed allogeneic stem cell transplantation. Distinction from graft-versus-host disease in the allogeneic setting however, has been difficult. Recent experience with non-myeloablative conditioning for stem cell transplantation, however, reveals that an engraftment syndrome independent of GVHD may occur. In some cases, this engraftment syndrome may be a manifestation of a host-versus-graft reaction (graft rejection). While cellular and cytokine interactions are believed to be responsible for these clinical findings, a distinct effector cell population and cytokine profile have not been defined. Engraftment syndromes are likely associated with an increased transplant-related mortality, mostly from pulmonary and associated multiorgan failure. Corticosteroid therapy is often dramatically effective for engraftment syndrome, particularly for the treatment of the pulmonary manifestations. A proposal for a more uniform definition of engraftment syndrome has been developed in order to allow for a reproducible method of reporting of this complication and for evaluating prophylactic and therapeutic strategies. Bone Marrow Transplantation (2001) 27, 893-898.
poietic stem cell transplantation (HSCT), these clinical manifestations have usually occurred immediately before or at the time of neutrophil engraftment. The term engraftment syndrome (ES) has, therefore, been most widely applied to describe this clinical entity. [1] [2] [3] [4] Other terms that have been used to describe this syndrome have included capillary leak syndrome (CLS), 5, 6 reflecting the clinical manifestations of diffusely increased capillary permeability, and autoaggression syndrome, signifying a possible immunological component in the autologous HCST setting. 7 In its most extreme form, in which profound hemodynamic collapse and multi-organ system failure may develop, the term aseptic shock syndrome has been applied. 8 The relationship between multiple organ failure, also termed multiple organ dysfunction syndrome (MODS), and ES is often indistinct. 9 Multi-organ failure can occur independent of engraftment, likely as a result of chemoradiotherapy-induced diffuse endothelial injury, diffuse inflammation and thrombosis. In some situations, however, this process is initiated, or at least aggravated, by neutrophil recovery. 1 Engraftment syndromes have usually been described following autologous HSCT. [1] [2] [3] 7 In the allogeneic stem cell transplant setting, the clinical sequelae of neutrophil recovery have often been ascribed to an early graft-versus-host response. With the use of a cyclophosphamide-based nonmyeloablative preparative therapy for allogeneic HSCT, however, an ES has been commonly seen without overt GVHD and in some cases is likely to be a manifestation of graft rejection. 10 This review will describe the clinical features of the variously described engraftment syndromes, speculate on the pathogenesis of these syndromes, and describe available therapies. Finally, recommendations will be made for a more uniform definition of this syndrome, hopefully encompassing the multiple settings in which it can occur.
Clinical features

Autologous stem cell transplantation
The reported clinical presentation of ES has varied, primarily due to the lack of uniform diagnostic criteria. The reported incidence of ES following autologous HSCT has also varied widely, again due primarily to how it was defined (Table 1) . A 7% incidence of ES was reported by Edenfield et al 3 who defined ES as a fever greater than 39°C, rash and evidence of pulmonary injury (either infiltrate or hypoxia). Ravoet et al 2 observed a similarly low incidence (9%) of engraftment syndrome which was defined by non-infectious fever, fluid retention and pulmonary interstitial infiltrates during early neutrophil recovery. Lee et al 1 however, defined the syndrome as rash and noninfectious neutropenic fever and observed these findings in 132 of 248 (59%) patients. Cahill et al 5 described a capillary leak syndrome (CLS) in temporal relationship to marrow engraftment as non-cardiogenic pulmonary edema with or without concurrent pleural effusions. This occurred in conjunction with multiple other manifestations of organ dysfunction (such as central nervous system disturbance, renal insufficiency and hepatic dysfunction) in 11 of 20 (55%) autologous bone marrow transplant recipients. Nurnberger et al 6 defined CLS as weight gain of Ͼ3% within 24 h and non-responsiveness to furosemide. Twenty of 96 (21%) patients receiving autologous or allogeneic BMT fulfilled these criteria.
The lack of well-defined criteria for the diagnosis of ES has also likely influenced the analysis of risk factors for its occurrence. Numbers of infused mononuclear or CD34-positive progenitor cells and speed of neutrophil recovery were predictive of ES in two series. 2, 3 In the analysis by Edenfield et al 3 the use of growth factor mobilized peripheral blood stem cells (as opposed to autologous bone marrow) was a risk factor for ES. Post-transplant granulocyte colony-stimulating factor increased the incidence of the syndrome in one series, 1 but not conclusively in others. 2, 3, 7 Conditioning with busulfan and female patients undergoing therapy for solid tumors were found to be risk factors in analyses by Ravoet et al, 2 and Edenfield et al, 3 respectively. Cahill et al 5 found that prior thoracic radiation therapy and amphotericin B therapy predisposed to the pulmonary manifestations of CLS. Lee et al 1 found that sepsis in the first week of neutropenia decreased the incidence of this syndrome and that the incidence was significantly higher after 1989 (following the introduction of aggressive prophylactic antibiotic therapy). In the Nurnberger series, 6 CLS occurred more frequently among recipients of unrelated donor BMT than matched related BMT and in allogeneic more than autologous BMT recipients with solid tumors.
An ES-associated rash following autologous SCT has been described as being similar to that of acute GVHD in the allogeneic transplant setting. In Lee's series, 1 the initial 23 patients with a rash had a skin biopsy performed which showed changes consistent with acute GVHD. Immunohistochemical analyses were performed which showed a prominent perivascular infiltration of CD2 + , CD3 + , CD5
+ and CD4 + cells. Moreb and colleagues, 7 in describing an 'autoaggression syndrome' following autologous HSCT, observed rashes in 55% of patients occurring at the time of white blood count recovery. Six (of 23) patients with rash had histologic evidence of GVHD. Histopathologic examination of the lung or analysis of bronchoalveolar lavage material during CLS demonstrated only hemorrhage and edema in Cahill's series. 5 At autopsy, however, pulmonary fibrosis was described as a prominent finding.
The risk of mortality among autologous stem cell transplant recipients with ES has also been variable. Most deaths have occurred as a result of respiratory failure with or without multiple organ failure. The mortality rate for patients with ES was 18% in Edenfield's analysis, 3 compared to an 8% mortality rate for the group as a whole. Nurnberger et al 6 reported a 60% mortality rate among patients with CLS compared with 14% of patients without CLS. In a series of 85 patients who underwent autologous HSCT for breast cancer, an increased risk of relapse and an increased rate of late mortality were observed in women who developed ES. 11 The mechanism of this adverse prognostic effect of ES remains obscure.
Allogeneic stem cell transplantation
Clinical manifestations of ES similar to those following autologous HSCT have often been attributed to an early graft-versus-host response in the allogeneic stem cell transplant setting. In perhaps its most dramatic form, Powles and colleagues 12, 13 described an abrupt and often fatal clinical syndrome of fever, rash, massive noncardiogenic pulmonary edema, often with renal failure and seizures, following haploidentical bone marrow transplantation. This syndrome, which has often been referred to as 'hyperacute GVHD' was likely the result of a cytokine cascade accompanying what Powles referred to as an 'in vivo mixed lymphocyte reaction'. In the setting of HLA-matched allogeneic HSCT following conventional myeloablative conditioning, particularly when methotrexate is used in conjunction with cyclosporine or tacrolimus, symptoms and signs accompanying neutrophil recovery are often less prominent. Nonetheless, Cahill et al 5 observed a similar incidence of CLS in predominantly HLA-matched allogeneic bone marrow transplant recipients and similarly conditioned autologous transplant recipients (18 of 35 vs 11 of 20 respectively) ( Table 2 ). Eleven allogeneic transplant recipients had clinical and pathologic evidence of acute GVHD. Seven developed CLS before the clinical diagnosis of GVHD, two concomitant with the diagnosis of GVHD and one during a rapid taper of corticosteroids. Nurnberger et al 6 also reported a high incidence of CLS (28%) among allogeneic BMT recipients, particularly following unrelated BMT.
With increasing experience with non-myeloablative preparative regimens for allogeneic HSCT, a changing spectrum of ES and GVHD has emerged. We have observed ES in the majority of recipients of HLA-matched donor BMT for hematologic malignancy who received a regimen consisting of cyclophosphamide, peritransplant antithymocyte globulin, pretransplant thymic irradiation and posttransplant cyclosporine. 10 Approximately three-quarters of patients have developed a non-infectious fever and rash often accompanied by transient hepatic dysfunction and fluid retention with or without noncardiogenic pulmonary edema. The onset of this syndrome has been early (a median of 1 day prior to neutrophil engraftment) and initial skin biopsies have not been diagnostic of GVHD in most cases. While this ES was likely an early manifestation of GVHD in some cases, as evidenced by pathologically documented GVHD during a subsequent taper of corticosteroids or following 'prophylactic' DLI, in other cases the ES was an apparent manifestation of a host-versus-graft alloresponse. In 19% of patients with ES, graft loss, as determined 14,15 However, with an alternative method of in vivo T cell depletion (monoclonal anti-CD2 antibody therapy; MEDI 507, Biotransplant, Inc., Charlestown, MA, USA) prominent manifestations of pulmonary CLS accompanied graft rejection (as determined by serial chimerism analyses and in vitro assays of cellular alloreactivity) in several patients. 15 
Pathophysiologic mechanisms of ES
The pathophysiologic mechanism of ES is multifactorial and may involve prominent cellular interactions of T cells, monocytes, and other effector cells, complement activation and proinflammatory cytokine production and release. [16] [17] [18] [19] [20] [21] The pathogenesis of the syndrome is dependent upon the intensity of the preparative regimen (with distinction made between those considered to be myeloablative and the more recently described nonmyeloablative preparative strategies) [22] [23] [24] and donor source of the stem cells (allogeneic vs autologous). 5, 6 Epithelial and endothelial injury from highly cytotoxic conditioning regimens with release of proinflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-␣) and interferon gamma and the effects of early cytokine production on subsequent cellular and cytokine interactions has been well described. [16] [17] [18] [19] [20] [21] In the allogeneic transplant setting, increased levels of TNF-␣ has been a predictor of later GVHD and other transplant-related complications. 25 Certain drugs (alkylating agents) 26 and total body irradiation 27 may be toxic to pulmonary endothelium, thus predisposing to subsequent pulmonary edema and in some cases, hemorrhage. [27] [28] [29] During neutrophil recovery, following cytotoxic chemotherapy or stem cell transplantation, a spiraling production and release of cytokines and products of neutrophil degranulation and oxydative metabolism occurs leading to local (such as in the lung where the neutrophils may be initially sequestered) and systemic (eg fever and a diffuse increase in capillary permeability) tissue injury. Multiple cytokines have been implicated in the pathogenesis of ES, including those predictive of GVHD and multi-organ failure, 25 those which are likely mediators of CLS (IL-2, TNF-␣, INF-gamma) 30, 31 and IL-8, which is integral to neutrophil regeneration and function. 32, 33 There has, however, been no well-defined characterization of the cytokine profile of ES.
In the allogeneic transplant setting, the complex mechanisms of an alloresponse (either GVH or HVG) involving activated T cells and pro-inflammatory cytokines, upregulation of adhesion molecules and histocompatibility antigens, and tissue injury via cytokines and recruited effector cells, probably contribute to the clinical picture of ES. [16] [17] [18] [19] [20] [21] 34 A similar initial presentation and responsiveness to therapy to that of ES following autologous HSCT, suggest however, that the earliest clinical manifestations of this syndrome may have the same pathogenesis. The observation that graft rejection may lead to an identical clinical presentation as an early graft-versus-host reaction following non-myeloablative preparative therapy suggests that competing HVG and GVH responses may be operative in a state of mixed lymphohematopoietic chimerism and that these cellular interactions (and subsequent cytokine production and release) may be magnified in this setting.
The observation that histopathologic changes of acute GVHD are often seen in skin biopsies of patients with autologous ES suggests that there is an important clinical and pathophysiologic interface of ES and autologous GVHD. 7 Thus, autoreactive lymphocytes and lack of regulatory suppressor mechanisms in the early post-autologous transplant setting, may be important in the pathogenesis of this syndrome.
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Therapy of ES
Therapeutic guidelines for ES have not been well established. Mild ES following autologous HSCT (eg transient low grade fevers with limited rash) may not require therapy, as resolution of these clinical signs following full hematologic recovery and discontinuation of growth factors, antibiotics, etc, is not uncommon. For patients with progressive or symptomatic ES, particularly with pulmonary involvement, corticosteroids are often dramatically effective. Improvement following therapy with corticosteroids was noted in six patients with multiorgan involvement in the Cahill study. 5 In more than 90% of the cases described by Lee et al, 1 there was prompt defervescence within a median of 1 day following the administration of corticosteroids. Thirty-one of 37 hypoxic patients recovered in a median of 3 days. Three of four patients who died of ARDS did not receive corticosteroids. Nurnberger et al 36 reported a favorable outcome for the majority of patients with severe CLS who received C1 esterase inhibitor concentrates, suggesting an important role of complement activation in this syndrome.
Not surprisingly, respiratory failure requiring intubation and mechanical ventilation has been associated with a high mortality rate in most series. [37] [38] [39] However, given the potentially self-limiting nature of this illness, particularly in the autologous setting, survival with intensive supportive care may be more likely than in the setting of idiopathic interstitial pneumonitis following HSCT. 40, 41 High-dose corticosteroids have been particularly beneficial in patients with diffuse alveolar hemorrhage. 28, 42, 43 All patients with an ES following our non-myeloablative allogeneic transplant protocol received corticosteroids at a dose of 0.5 to 10 mg/kg per day (median 1 mg/kg per day). 10 All of these patients achieved complete resolution of symptoms and signs of ES, although approximately half of the patients had a recurrence of these symptoms (or development of acute GVHD) during a rapid taper of the corticosteroids in preparation for a 'prophylactic' DLI.
Supportive care of patients with ES should include appropriate anti-infective prophylaxis, given a heightened risk of (and the masking of signs of) infection in neutropenic patients receiving corticosteroids. Given a depleted intravascular volume, secondary to increased capillary permeability, loop diuretics should be used judiciously. This is particularly true in the allogeneic setting where further intravascular volume depletion can potentiate the nephrotoxicity of cyclosporine or tacrolimus. Renal dose dopamine is often used to improve renal perfusion, but controlled trials evaluating the efficacy of dopamine in this setting are lacking.
Proposal for a uniform definition of ES
ES is at present an entirely clinical entity with no pathognomonic histopathologic change or biochemical marker. Considering the most commonly reported clinical manifestations of ES, ie fever, rash and noncardiogenic pulmonary edema, the following diagnostic criteria are proposed.
Major criteria
• Temperature of у38.3°C with no identifiable infectious etiology.
• Erythrodermatous rash involving more than 25% of body surface area and not attributable to a medication.
• Noncardiogenic pulmonary edema, manifested by diffuse pulmonary infiltrates consistent with this diagnosis, and hypoxia.
Minor criteria
• Hepatic dysfunction with either total bilirubin у2 mg/dl or transaminase levels уtwo times normal.
• Renal insufficiency (serum creatinine of уtwo times baseline).
• Weight gain у2.5% of baseline body weight.
• Transient encephalopathy unexplainable by other causes.
A diagnosis of ES is established by the presence of all three major criteria or two major criteria and one or more minor criteria. ES should occur within 96 h of engraftment (neutrophil count of у500/l for 2 consecutive days). This proposed time-frame is based on the temporal occurrence of symptoms and signs of ES that we have observed following non-myeloablative allogeneic HSCT. 10 In the setting of allogeneic HSCT, additional clinical and pathologic symptoms and signs of GVHD should at least initially be absent.
Conclusions and future direction
ES following HSCT cannot be easily separated from either multiple organ dysfunction syndrome whose predisposing factors (cytotoxic chemoradiotherapy induced endothelial and epithelial injury, proinflammatory cytokine release during neutrophil recovery, etc) are probably identical, or in the allogeneic transplant setting, from GVHD. However, distinctive clinical features of the engraftment process (ie recovery of neutrophils following stem cell transplantation) have been well described and are important to recognize both for their therapeutic implications and for the design of clinical trials aimed at prevention of ES. These proposed criteria for the diagnosis of ES should allow for a more uniform method of reporting this complication and for determining optimal prophylactic and therapeutic strategies. Efforts should be made to define the cellular composition and cytokine profile that characterize this syndrome. Given the likely cellular and cytokine mediators of this syndrome, future efforts may focus on drugs or antibodies which interfere with these proinflammatory cytokines and the consequent upregulation of adhesion molecules or histocompatibility antigens which modulate specific effector cell function.
